Althoughd rugi nteractions withw arfarin area ni mportant cause of excessive anticoagulation, theiri mpact on ther isko f seriousbleeding is unknown.We therefore performedacohort study andanestedcase-controlanalysis to determine the risk of serious bleeding in 4152 patients (aged 40-84 years) with nonvalvular atrial fibrillation (AF)t akingl ong-term warfarin (>3 months).The study populationwas drawn from theUKGeneral Practice ResearchDatabase.Morethan half(58%)ofeligible patients used potentiallyinteracting drugs during continuous warfarin treatment. Among 45 identifiedcasesofincidentidiopathic bleeds (resulting in hospitalisation within 30 days or death within 7days) and143 matchedcontrols,morecasesthan controls took ≥ 1p otentially interacting drugw ithin the preceding Keywords Atrial fibrillation, bleeding, druginteractions,warfarin 30 days (62.2% vs.35.7%)a nd used >4 drugs (polypharmacy) within the preceding 90 days (80.0% vs.66.4%). Conditionallogistic regression analysis yielded an odds ratio (OR) of 3.4(95% confidence interval [CI]: 1.4-8.5) forthe risk of serious bleeding in patients treatedw ith warfarin and ≥ 1d rugs potentiallyi ncreasing the effect of warfarin vs. warfarin alone adjustedf or polypharmacy,diabetes, hypertension,heart failure, and thyroid disease;the adjusted OR forthe combined useofwarfarin and aspirinv s. warfarin alone was 4.5 (95%C I: 1.1-18.1). We conclude that concurrent useo fp otentially interacting drugs with warfarin is associated with a3to4.5-fold increasedriskofserious bleeding in long-term warfarin users.
Introduction
Warfarin has been showni nc linical trials to be effectivef or strokeprophylaxis in patients with atrial fibrillation (AF) (1) .In clinical practice, however, achieving effectivea nd safea nticoagulation with warfarin is difficultbecausethe anticoagulant effect canbeinfluencedbymanyintrinsic and extrinsic factors (2) (3) (4) (5) . In particular, drug interactions with warfarin are amajor causeofexcessive anticoagulation (2) (3) (4) (5) and hence could be an important causeofbleeding in patients taking warfarin.Use of warfarin in patients with chronic non-valvular AF is of particular concernsincethese patients aretypicallyelderlywith multiple co-morbiditiesrequiring concomitant drug therapies increasing the risk for drug-drug interactions.
Most documented interactionsw ith warfarin are based on small case series or single cases,orhavebeen extrapolatedfrom in-vitro or animal studies (6) .Afewe pidemiologicals tudies have estimatedthe risk of bleeding during concurrentuse of oral anticoagulants and other specificdrugs, including paracetamol, aspirin and other platelet-inhibiting drugs, or NSAIDS(7-10), butasystematic investigation is lacking.
The objective of the present study,therefore,was to investigate the association between warfarin and the concurrentuse of potentiallyinteracting drugs and the risk of serious bleeding in patients receiving warfarin for prevention ofAF-related stroke.
Materials andmethods

Study design
We conducted alongitudinal follow-up study of patients with AF treatedwith warfarin to estimate the effect of concomitant use of potentiallyinteracting drugs on the incidenceofseriousbleeding (resulting in hospitalisation or death),with anestedcase-control analysis to furtherquantify the risks adjusted for potential confounders.
Study population
The study population wasdrawn from the General PracticeResearch Database(GPRD), acomputerised database of longitudinal patient records collected from apanel of general practitioners (GPs) in the UnitedKingdom. Participating GPs use computers in their offices to record patient medical information sucha s demographics, 's ignificant'medical diagnoses,outpatient visits, hospitalisations and prescribed drugs. The validity of the database with regard to quality and completenessofthe data has been extensively documented (11) .
The study cohortc onsisted of patients with AF (aged 40-84 years), permanentlyregistered with one of the participating practices during the studyp eriod (January1 991 to April 2001), whohad afirst ever warfarin prescription for AF during the studyperiod and continuedtreatment for morethan 90 days. Patients were excluded if theyhad an increased risk of bleeding duet o( a) pre-existing conditions (prior coagulation disorders, cancer,peptic ulcer disease, alcohol or drug abuse), (b)history of major bleeding prior to starting warfarin treatment, or (c) high-intensity warfarin therapya ssociatedw ith ap rosthetic heartvalve.
Follow-up
Patients in this cohortw ere followedf rom day9 0o fw arfarin treatment (Start date)u ntil the earliest of (End date): warfarin discontinuation or break in warfarin exposure,occurrence of an incident bleed of anyseverity,the development of an exclusion diagnosis (coagulation disorder etc.), pregnancy, age 85 years, death or end of study period.
Warfarin exposure
We could not directly estimate the duration of warfarin treatment from the number of tabletsprescribed becausewarfarindosages are generally not fixed, and dosage instructions are most commonlyrecorded in the computerrecords as "as directed". Periods of current warfarin exposure were therefore determinedb ya ssuming an exposure duration of 90 days per prescription, i.e. warfarin exposure wasd eemed to be continuous providedt hat the intervalbetween prescriptions did not exceed 90 days.Inthe event of morethan 90 days betweenprescriptions,current exposure wasdeemed to end 90 days after the last prescription. We followedpatients onlyduring the first period of continuous warfarinexposure,starting on day90oftreatment and ending on the last dayoffollow-up or the last dayofcontinuous treatment. The first 90 days of treatment were excluded fromour analysis becausehigherrates of bleeding are generally observedduring this period due to pre-existing lesions and INRf luctuations during treatment initiation (12) .
Concomitant exposuretopotentially interacting drugs
We selected the British NationalFormularyasareference forpotentiallyinteracting drugs that mayincrease the effects of warfarinorwith antiplateleteffect because it is an important, unbiased source of reference information for GPsi nt he UK and is the sourceofinformation on potential drug interactions referenced in the BritishSociety for Haematology guidelines on oralanticoagulation (13, 14) . Of the manydocumented potential drug interactions with warfarin,the drugs we studiedwere only thosefor whichappropriate, clinicallyrelevant information wasavailable during the study period (2, 6, 15, 16) to increase the specificity of our analysis. The list of drugs is, additionally, very similar to the interacting drugs mentioned in the recently published American CollegeofChest Physician guidelines on antithrombotictherapy (17) . We defined interacting drugs as those listed as "enhancing or possibly enhancing the effect of warfarin"or"increasing the risk of bleeding duetoantiplatelet effect" in combination with this agent (13) .These included analgesics, antibacterial drugs, antifungals, antiplateletdrugs, hormone preparations, anti-lipidaemic drugs, non-steroidal anti-inflammatoryd rugs (NSAIDs),s electives erotonin reuptake inhibitors( SSRIs), ulcer-healing drugs, allopurinol, and amiodarone ( oralformulations of these agents were considered; the exception wasm iconazole, forw hich oralg elsa nd intravaginal preparations were considered becausecasereportsindicate that miconazole is sufficiently systemicallya bsorbedf rom such preparations to interact with otherdrugs (6).Wedid not include penicillins in our studybecausethese agents arenot establishedasincreasing the anticoagulant effect of warfarin (13) . There is some evidencet hat amoxicillinm ay be associated with an increased risk of over-anticoagulation, butitisunclear whether the underlying febrile diseaseoramoxicillin maycauseanexcessive warfarinresponse (3, 18, 19) . Forthe case-control analysis, interacting drugs were furthersubdivided into twocategories: (a)drugs that mayi ncrease the warfarin effect as measured by the INR, and (b)agents that mayinhibit haemostasis (i.e.aspirin, clopidogrel,dipyridamole,and ticlopidine).
Duration of exposure to potentiallyi nteracting drugs was basedonthe actual prescription duration, whichw as estimated by dividing the number of tablets by the prescribed daily dose. We estimatedt he total duration of potentiallyi nteracting drug exposure during current continuous warfarin exposure starting with the first potentiallyinteracting drug taken after January 1, 1991.
Case definition, ascertainmentand validation
Patients whoexperienced incident idiopathic bleeds during continuous warfarin exposure that resulted in hospitalisation within 30 days or death within 7daysfollowing the bleeding event were definedascases.Bleeds were considered non-idiopathic if they were post-surgical,d ue to trauma or due to ac oagulation disorderoranother clinicalcondition (e.g. infection at the siteofthe bleed).
All incident bleeds occurring during the follow-up period were identifieda nd reviewedb yt wo independent reviewers, blindedtothe patient'sdrugexposure status, to identify potential (hospitalised/fatal) cases. To ensurecomplete ascertainment of haemorrhagic strokes, all strokes and cerebrovascularaccidents not specified as ischaemic were additionallyi dentified and reviewed, as were the records of all patients whodiedduring follow-up where the causeofdeathwas unknown, non-specific and/ or consistent with bleeding as acontributoryfactor (e.g. sudden death, pneumonia, septicaemia, cerebrovasculard isease, anaemia). Forall potentialcases identifiedwherethe patient wasstill alive, aq uestionnaire wass ent to the patient'sG Pt oa scertain whether the patient hadbeen hospitalisedasaresultofthe bleed and to establish anyknown contributorycauses other thanwarfarin. We additionallyobtained copiesofhospital lettersfrom the GP and requestedinformation from the GP about the INRatthe timeofthe bleed wherebythis wasnot generallyavailableinthe GPs' records. Where the event wasfatal,weobtained death certificates.
Cohortand case-control analyses
We calculated the incidenceofserious(hospitalised/fatal) bleeds by dividing the number of incident bleeding eventsduring current continuous warfarin exposure by the number of patientyears of exposure.Wealso calculated incidencerates forserious bleeds during currentw arfarinexposure with and without concurrent use of potentiallyinteracting drugs.
Forthe case-control analysis, cases were matchedwith up to 6warfarin-exposed controls on the basis of age (± 3years if no exact match),gender,practice and indexdate, where the index date wasthe date of each case'sbleeding event.Cases and controls were definedasexposed to apotential warfarin interaction if an interacting drug has been prescribed within 30 days prior to the bleeding event (cases)orindexdate(controls).Bydefinition, both cases and controls were exposed to warfarin on the date of prescription of the potentiallyi nteracting drug. Polypharmacy wasdefinedastreatment with morethan 4prescription drugs including warfarin in the 30 days preceding the indexdate.
We used conditional logistic regression to estimate oddsratios and their 95% confidenceintervals (CI) for the risk of serious bleeding associatedwith exposure to potentiallyinteracting drugs in combination with warfarin compared with exposure to warfarin alone, adjustedfor diabetes, hypertension, heart failure, thyroid disease, and polypharmacy. All analyses were performed using STATA7 .0 (Statistics/Data Analysis, College Station, Texas, USA).
Results
We identified4152 eligible patients with AF commencing longtermw arfarint herapyd uring the study period. Fiftye ight percent of patients were male and 57%were aged 70 years or older. Female patients tendedtobeolder; 69%offemalepatients were older than70years compared with 49% of male patients.
Cohortanalysis
We observedatotal of 3740.8 patient-years of continuous warfarinexposure among the 4152 patients in the study cohort; these patients received an averageo f1 1.6 (median 4) warfarin prescriptions during follow-up before abreak in treatment occurred. Thirty-three percent of patientsreceivedw arfarincontinuously for morethan ayear.This group contributed 1587.4 patient-years of continuous warfarin exposure,i.e. 43.5% of all observedcontinuous exposure time. More than half (58%)ofthe 4152 patients were exposed to potentiallyinteracting drugs at some timeduring currentcontinuous warfarin exposure and,o verall,patients were exposed to potentiallyinteracting drugs more than one third (37%)ofthe time(Table2).
Some2 283 patients were censored before the end of the studyp eriod duet ot he end of continuous warfarin treatment without developingab leeding event or anothere xclusion criterion while 1869patients were continuouslytreated until they were censored from the cohortfor other reasons: 432 developed ab leed of anyseverity,187 were censored duetoane xclusion criterion, 1becamepregnant,33reached the age of 85,133 died and 1083 reached the end of the study period.
Of the 432 observedb leeding eventsa nd 133 patients who died during follow-up, we identifiedatotal of 340 incident idiopathic bleeds of anyseverity,ofwhich 294 were of minor or moderateseverity and 46 were classified as cases (7 fatal; 39 hospitalisednon-fatal). Five of the cases involved intracranialbleeding (3 fatal, 2hospitalised non-fatal), 15 of the bleeds were gastro-intestinal(3fatal,12hospitalised non-fatal), 13 of the cases experienced epistaxis (all hospitalised non-fatal), and the re-maining 13 bleeds occurred at varioussites, includingone fatal pleural haemorrhage.
Overall, the crude incidenceo fs eriousb leeding (fatal and non-fatal) during currentcontinuous warfarin exposure was1.2 per 100 patient-years at risk (PYAR).The rate varied according to whether or notthe patient wasconcomitantlyexposed to potentiallyinteracting drugs. During warfarin exposure alone the rate was0.9 serious bleeds per 100PYA R, increasing to 1.8 serious bleeds per 100PYA Rduring periods of concomitant exposure to potentiallyi nteracting drugs (incidencer ater atio: 2.05 [95%CI: 1.1-3.9]).
Of the 88 potentiallyi nteracting drugs consideredi nt his analysis, 56 were takenconcomitantlyb yw arfarinusers. Eight of these drugs were involved in 25 non-fatal and in 3fatal bleeding events( 2G I-bleeds,1p leural haemorrhage) ( Table 3) . Bleeding sites amongpatients whousedwarfarinincombination with aspirin were epistaxis, purpura,haematemesis and melaena, none of themwas fatal.
Thehighest incidencerates,although onlybased on onecase each, were found for miconazoleand metronidazole.Inboth patients, the potentiallyinteracting drug wasnewly added. In the first patient, miconazolewas administered as an oral gel for the treatment of mouth sores;the patient wasadmitted with spontaneous bleeding and aprothrombin indexof>5min 17 days after miconazoleh ad been added. Thep atient wasa lso al ong-term user of paracetamol. The second patient wasa dmitted with haemorrhage and an INRof4.5 twodaysafter oral metronidazolewas started forthe treatment of askin infection. We did not find evidenceofbleeding eventsassociatedwith anyotherantibacterials. Sulfamethoxazolew as only prescribed to 8p atients (0.1PYA R),trimethoprimto209 patients (6 PYAR), macrolides to 194 patients (5.5 PYAR), and quinolones to 104 patients (2.6 PYAR) during continuous warfarin use.
Dosage information wasa ssessedf or paracetamol and aspirin use. The averaged aily documented dose for paracetamol among cases varied from 885mgto2900 mg, and had beenprescribed for at least4weeks prior to their bleeding events. Doses for aspirin varied from 75 mg to 325 mg/day.
Exposure to non-aspirin NSAIDS waslow in this population (100.9P YA Ra ll combined)a nd none of the non-aspirin NSAIDSwas involved in ableeding event.
We obtained information on INRs at the timeofthe bleed in 7c ases:E xcessive anticoagulation wasp resenti nt he twop atients on miconazolea nd metronidazole,s ee above;fivec ases had INRsw ithin the therapeutic rangef or strokep rophylaxis (2.0-3.0) of which2were notexposed to potentiallyinteracting drugs and 3were exposed to paracetamol (n=2) and allopurinol (n=1).
Nested case-control analysis
The case-control analysis wasb ased on 45 cases and 143 matchedcontrols (no matchedcontrols could be found for the remaining case, a7 0-year-old man whoe xperienced epistaxis while exposed to warfarin butnot taking anydrugs known to interactwith this agent),all of whom were exposed (bydefinition) to currentcontinuous warfarin at the indexdate. Thecharacteristicsofcases and controls are shown in Table4.The distribution of sexd iffers between cases and controls becauseo fu nequal numbersofobtainable matchedcontrols per case. Twenty-eight cases (62.2%)and 51 (35.7%)controls were exposed to potentiallyinteracting drugs or antiplateletagents in combination with warfarin. Crudeodds ratios were 3.2(95% CI: 1.5-7.1) for the risk of serious bleeding associatedw ith the use of drugs thatm ay increasethe effect of warfarin compared with warfarin alone, and 3.6( 95% CI: 1.0-12.6) for the risk associated with the use of antiplateletagents in combination with warfarin compared with warfarin alone. After adjusting for co-morbiditiesand polypharmacy,the adjusted odds ratios were 3.4(95% CI: 1.4-8.5) and 4.5 (95% CI: 1.1-18.1), respectively (Table 4) .
Table5shows the potentiallyinteracting drugs prescribed to cases and controls during the 30 days prior to the indexdate. Six cases were concomitantlyexposed to more than one potentially interacting drug in combination with warfarin;t hreep atients took paracetamol in addition to levothyroxine,omeprazole, and miconazolerespectively, twopatients were exposed to aspirin in addition to allopurinol and amiodarone respectively,and one patient wasexposed to allopurinol and amiodarone. 
Discussion
In this observationals tudy of UK patients receiving long-term therapyw ith warfarin for prevention of AF-related stroke, we found thatp otentiallyi nteracting drugs were used in combination with warfarin for morethan one third of the timea nd that more than half of the patients were exposed to apotential interaction during the study period. We found a3 -foldi ncreased risk of bleeding leading to hospitalisation or deathi nw arfarin usersc oncomitantlyt aking potentiallyi nteracting drugs, and a 4.5-fold increased risk for patients using aspirin in combination with warfarin.
Morethan half of the patients (61%)with aseriousbleeding event in our studywere exposed to potentiallyinteracting drugs or an antiplateletagent in combination with warfarin before the bleeding event.This proportion is comparablewith the results of arecent (uncontrolled) trend study in the US in hospitalizedpatients with warfarin-associated haemorrhagew here6 2% used drugs known to potentiate the bleeding risk before the bleeding event (20) .All fatalc ases in thats tudy were taking potentially potentiating drugs comparedwith 3out of 7fatal bleeding cases in our study.C asef atality mayv aryb etween differentc linical settings or countries depending on anticoagulation monitoring and the management of the drug-drug interactionsand over-anticoagulation. Therateofseriousb leeding observed in our studyislower thanthat reported in apreviousGPRD study(1.2 vs. 3.1 bleeds per 100PYA Rinpatients with AF) (21) .The rates,however,are notd irectly comparable sincei nt he present study we deliberatelye xcludedp atients with pre-existing conditions associated withanincreased risk of bleeding (e.g. cancer,peptic ulcer disease), and we additionallyexcludedthe initiation phase of treatment when the risk of bleeding is highest (12) . Alower rateof bleeding is therefore unsurprising in our cohortatalowerunderlying risk of bleeding thanthe study population of Hollowell et al.(2003) .
These restrictions mayalso explain the differing result of a recently published study that did not find anysignificant association between drug interactionsa nd major bleeding (OR 1.33; 95% CI 0.96-.86) (10) .The study included patients with other major bleeding risk factorsa nd patients whoh ad just started treatment (40%) and were therefore at an increased risk of bleeding irrespective of potential drug interactions (10) .M oreover, drug-drug interactions areasub-group of adverse drug reactions whicha re predictablea nd therefore preventable in most instances (22) .Thus the strength of the association betweenpotentiallyinteracting drugs and adverse outcomes (the drug interaction) stronglydepends on the awarenessand management of potentiallyinteracting drugs by treating physicians.
Ourstudy confirmsthe resultsoftwo recent studiesthat reported that concurrent antiplatelettherapywas independentlyassociatedwith an increased risk of major bleeding (10, 23) . However,our estimate is higher with wide confidenceintervals.
Of the 88 interacting drugsi ncludedi no ur analysis only8 were involved in seriousb leeding eventsi nt he present study (11) .Although our studywas notdesignedtoevaluate the risks associatedwith individual drugs, the estimatedcrude incidence rates suggest ap ossible increased risk of bleeding associated withthe use of warfarin in combination with paracetamol (alone or in combination with otheranalgesics), allopurinol, metronidazole, miconazole, omeprazole, or aspirin. However, 6o ft he cases were exposed to more than one potentiallyinteracting drug and since we analysed each drug separately, our methods will have overestimatedt he risks associated with some of these drugs. While allopurinol, metronidazole and miconazole have previouslybeen reportedtocauseclinical relevant drug interactions (2, 6, 24, 25) , our findings add to the evidencethat paracetamol mayincrease the risk of bleeding amongw arfarinusers. Most patients were 'heavy'p aracetamol users taking dosages above the Hylekthreshold of 9.8 gper week and had been prescribedparacetamol foratleast4w eeks prior to their bleeding events ( 5) . It has beens uspected that the association between paracetamol use and increased risk of bleeding mayb ed ue to confounding by indication (7); paracetamol is generallyc onsideredsafer thanaspirin in combination with warfarin because it doesnot affect platelets or cause gastric bleeding.Inthe present study,weexcludedpatients whomight have avoided aspirin due to the risk of GI bleeding (i.e. thosewith pre-existing pepticulcer disease, historyo fG Ib leeding or alcohol abuse), so we considerthis unlikelytoexplain the association betweenparacetamol use and increased risk of bleeding.
It is worthn oting that the warfarin-miconazolei nteraction canoccur with oral gel formulations of miconazole (6, 26) . Physicians should therefore closely monitorthe patient'sINR for an adequate periodevenifmiconazoleisgiven as an oral gel formulation.
The patternofinteracting drugs among cases in our study differedfrom the one reported by Kucher et al.wherethe most commonlyuseddrugs were quinolone antibiotics(32%),levothyroxine (15%), simvastatin (10%), and amiodarone(10%) (20) .Patternsofinteracting drugs mayvaryindifferent clinical settings or countries because of differences in the use of drugs and knowledge about potentialdruginteractions.
Our study has some limitations:firstly, we mayu nderestimate the risk of bleeding episodesdue to drug interactions with warfarin becausew eh ad no information on over-the-counter drugs(in particularparacetamol,aspirin, or otherNSAIDs)and herbal or nutritional products, whichcan also interact with warfarin (24) . Furthermore,our definition of exposure to potentially interacting drugsdid not differentiate between newlystarted and long-termtherapies, nor did we considerthe impact of changes in dosage.Sincechangesindruguse maypose agreater risk of over-anticoagulation, this mayhavedilutedthe observedeffect. Many of the bleeds involving allopurinol, amiodarone, and paracetamol,h owever,o ccurred during chronic use.F or allopurinol and amiodarone, an effect on prothrombin timehas been observed when the drugs are started whereas the effect of paracetamol seemstobedose-dependent and related to the duration of exposure (6) .W hile it would have beenp ossible to refine our analysis to focus on periods of exposure immediatelyfollowing therapyc hanges, the appropriate exposure timew indows for such an analysis are unclear,particularlyinthe case of amiodarone and paracetamol. As econdl imitation is the lack of INR data. It has recentlyb een reportedt hat drug interactions with warfarin mayl ead to over-anticoagulation (27) a nd that overanticoagulation increases the risk of bleeding 3-fold in patients with atrial fibrillation (28) and up to 6-fold in an unrestricted patient population with different indications for warfarin treatment (29) . Unfortunately INR dataw ere generally not availablef or analysis in the present study becauseI NR valuesa re typically documented in patient booklets rather than in the GP office computer in cases where the patient attends ahospital clinic for INR monitoring.Wewere only able to obtain information on INRsat the time of the bleed in 7patients, five of whom had INRs within the therapeutic range for strokeprophylaxis (2.0-3.0). Though the risk of over-anticoagulation maybeprevented by increasing the frequencyo fm onitoring (and,i nt urn, warfarin dosagea djustment) when patients are exposed to interacting drugs, we had no means of assessing whether the treating physicians actively managedany potential drug interactions in the latter patients by increasing the frequencyofINR monitoringand warfarin dosage adjustment. Moreover, drug interactions with warfarin do not necessarilyresultinINR changes. Whileinhibitors of warfarin metabolism, e.g.amiodarone, or drugsthat change the kinetics of clotting factors, e.g.levothyroxine, mayincrease INRlevels (pharmacokinetic effects) additive effectsofwarfarinincombination with adrugwith plateletinhibiting propertiesmay not be detectedb yI NR monitoring( pharmacodynamic effects). Indeed, arecent study found thatserial INRsare poor predictorsof haemorrhagic eventsinpatients receiving long-termanticoagulation treatment and reported the majority of bleeding events withI NRsi nt he therapeutic range (30) .C onsequentlys tudies thatinvestigated the association of oral anticoagulants and interacting drugs and over-anticoagulation (INR >6.0) as aproxy for bleeding risk might have underestimated the total bleeding risk of the combined useofwarfarinand interacting drugs.
In conclusion, our study demonstrates that drug interactions areanindependent risk factor forseriousbleeding in patients on long-termw arfarint herapyf or strokep rophylaxis, and thatl evels of usage of suchpotentiallyinteracting drugs arerelatively high. An eed therefore exists not onlyt oi ncrease awareness amongphysicians on howbesttominimise the risksassociated withthe use of interacting drugs, butalso for practical guidance regarding the timing, frequencyand duration of additional monitoring requiredwhen specific drugs areusedinconjunction with warfarin.
